---
layout: default
title: Prednisolone
description: "Prednisolone çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚ä¸­ç­‰è­‰æ“šç­‰ç´š L3ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 138
evidence_level: L1
indication_count: 10
---

# Prednisolone

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L3</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Prednisoloneï¼šå¾æ¿•ç–¹æ¨£çš®è†šç‚åˆ°æ–‘ç¦¿ (Alopecia Areata)

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Prednisolone å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Prednisolone åŸæœ¬ç”¨æ–¼æ²»ç™‚æ¿•ç–¹æ¨£çš®è†šç‚ç­‰éæ•æ€§æˆ–ç™¼ç‚æ€§çš®è†šç–¾æ‚£ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**æ–‘ç¦¿ (Alopecia Areata)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **14 å€‹è‡¨åºŠè©¦é©—**å’Œ **8 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | æ¿•ç–¹æ¨£çš®è†šç‚ã€èŸ²å’¬å‚·ã€å°¿å¸ƒç–¹ã€çš®è†šæ”ç™¢åŠéæ•æ€§æˆ–ç™¼ç‚æ€§çš®è†šç–¾æ‚£ç­‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | alopecia areataã€alopecia mucinosaã€telogen effluviumã€Quinquaud's folliculitis decalvansã€alopecia antibody deficiencyã€hereditary hypotrichosis with recurrent skin vesiclesã€alopecia-intellectual disability-hypergonadotropic hypogonadism syndromeã€atrichia with papular lesionsã€prolapse of lacrimal glandã€Sjogren syndrome |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.99% |
| è­‰æ“šç­‰ç´š | L3 |
| å°ç£ä¸Šå¸‚ | âœ“ å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 20 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. alopecia areata</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

<p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ">
ç›®å‰ç¼ºä¹è©³ç´°çš„ä½œç”¨æ©Ÿè½‰è³‡æ–™ã€‚æ ¹æ“šå·²çŸ¥è³‡è¨Šï¼ŒPrednisolone æ˜¯ä¸€ç¨®é¡å›ºé†‡è—¥ç‰©ï¼Œå…·æœ‰æŠ—ç‚å’Œå…ç–«èª¿ç¯€ä½œç”¨ã€‚
å…¶æˆåˆ†åœ¨æ²»ç™‚éæ•æ€§å’Œç™¼ç‚æ€§çš®è†šç–¾ç—…ä¸­çš„ç™‚æ•ˆå·²è¢«è­‰å¯¦ï¼Œæ©Ÿè½‰ä¸Šå¯èƒ½é©ç”¨æ–¼æ–‘ç¦¿é€™é¡è‡ªé«”å…ç–«æ€§ç–¾ç—…ã€‚
</p>

<div class="key-takeaway">
æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT03616964](https://clinicaltrials.gov/study/NCT03616964) | Phase 3 | å®Œæˆ | 778 | ç ”ç©¶ Baricitinib åœ¨ SLE æ‚£è€…ä¸­çš„æ•ˆæœå’Œå®‰å…¨æ€§ã€‚ |
| [NCT05162586](https://clinicaltrials.gov/study/NCT05162586) | Phase 2 | å®Œæˆ | 456 | ç ”ç©¶ Enpatoran åœ¨ SLE å’Œ CLE æ‚£è€…ä¸­çš„æ•ˆæœå’Œå®‰å…¨æ€§ã€‚ |
| [NCT04835441](https://clinicaltrials.gov/study/NCT04835441) | Phase 2 | å®Œæˆ | 76 | ç ”ç©¶ ALPN-101 åœ¨ä¸­é‡åº¦ SLE æ‚£è€…ä¸­çš„æ•ˆæœã€‚ |
| [NCT03843125](https://clinicaltrials.gov/study/NCT03843125) | Phase 3 | çµ‚æ­¢ | 1147 | é•·æœŸç ”ç©¶ Baricitinib åœ¨ SLE æ‚£è€…ä¸­çš„æ•ˆæœå’Œå®‰å…¨æ€§ã€‚ |
| [NCT07101471](https://clinicaltrials.gov/study/NCT07101471) | N/A | å®Œæˆ | 296 | è©•ä¼° RhofanibÂ® (Tofacitinib) åœ¨æ–‘ç¦¿æ‚£è€…ä¸­çš„å®‰å…¨æ€§å’Œæ•ˆæœã€‚ |
| [NCT01167946](https://clinicaltrials.gov/study/NCT01167946) | Phase 4 | å®Œæˆ | 42 | ç ”ç©¶å¤§åŠ‘é‡å£æœé¡å›ºé†‡åœ¨åš´é‡æ–‘ç¦¿ä¸­çš„å®‰å…¨æ€§å’Œæ•ˆæœã€‚ |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [37870096](https://pubmed.ncbi.nlm.nih.gov/37870096/) | 2023 | Meta-analysis | The Cochrane database of systematic reviews | æ–‘ç¦¿çš„æ²»ç™‚åŒ…æ‹¬å…ç–«æŠ‘åˆ¶åŠ‘ã€ä¿ƒé€²æ¯›é«®ç”Ÿé•·çš„è—¥ç‰©å’Œæ¥è§¸å…ç–«ç™‚æ³•ã€‚ |
| [30191561](https://pubmed.ncbi.nlm.nih.gov/30191561/) | 2019 | Systematic Review | The Australasian journal of dermatology | ç³»çµ±æ€§æ²»ç™‚åœ¨æ–‘ç¦¿ä¸­çš„æ‡‰ç”¨åŠå…¶æ•ˆæœã€‚ |
| [37992355](https://pubmed.ncbi.nlm.nih.gov/37992355/) | 2023 | Review | Dermatology practical & conceptual | ç ”ç©¶é¡å›ºé†‡è„ˆè¡ç™‚æ³•åœ¨æ–‘ç¦¿ä¸­çš„æ•ˆæœåŠå‰¯ä½œç”¨ã€‚ |
| [35986630](https://pubmed.ncbi.nlm.nih.gov/35986630/) | 2022 | Retrospective Study | Dermatologic therapy | ç ”ç©¶ç”²åŸºå¼·çš„æ¾é¾å–®ç¨æˆ–èˆ‡ç”²æ°¨è¶å‘¤è¯åˆæ²»ç™‚å»£æ³›æ–‘ç¦¿çš„æ•ˆæœã€‚ |
| [15692475](https://pubmed.ncbi.nlm.nih.gov/15692475/) | 2005 | RCT | Journal of the American Academy of Dermatology | ç³»çµ±æ€§é¡å›ºé†‡ä½œç‚ºè„ˆè¡ç™‚æ³•åœ¨æ–‘ç¦¿ä¸­çš„æ‡‰ç”¨ã€‚ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. alopecia mucinosa</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL4ï¼ˆæœ‰æ–‡ç»æ”¯æŒï¼‰

### è‡¨åºŠè­‰æ“š

**ç›¸é—œæ–‡ç»**ï¼šå…± 5 ç¯‡


</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. telogen effluvium</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL4ï¼ˆæœ‰æ–‡ç»æ”¯æŒï¼‰

### è‡¨åºŠè­‰æ“š

**ç›¸é—œæ–‡ç»**ï¼šå…± 1 ç¯‡


</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. Quinquaud's folliculitis decalvans</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL4ï¼ˆæœ‰æ–‡ç»æ”¯æŒï¼‰

### è‡¨åºŠè­‰æ“š

**ç›¸é—œæ–‡ç»**ï¼šå…± 2 ç¯‡


</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. alopecia antibody deficiency</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL4ï¼ˆæœ‰æ–‡ç»æ”¯æŒï¼‰

### è‡¨åºŠè­‰æ“š

**ç›¸é—œæ–‡ç»**ï¼šå…± 3 ç¯‡


</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. hereditary hypotrichosis with recurrent skin vesicles</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. atrichia with papular lesions</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.94%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. prolapse of lacrimal gland</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.94%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. idiopathic steroid-sensitive nephrotic syndrome</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.86%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.86%
- **è­‰æ“šç­‰ç´š**ï¼šL1ï¼ˆå¤šå€‹å¤§å‹ RCT æ”¯æŒï¼‰

### è‡¨åºŠè­‰æ“š

**è‡¨åºŠè©¦é©—**ï¼šå…± 8 é …

- è©¦é©—éšæ®µåˆ†å¸ƒï¼šN/A: 1é …, NA: 2é …, PHASE2: 2é …, PHASE3: 2é …, PHASE4: 1é …

**ç›¸é—œæ–‡ç»**ï¼šå…± 20 ç¯‡


</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å…§è¡›è—¥è£½å­—ç¬¬000590è™Ÿ | æ¨‚çˆ¾çˆ½è»Ÿè† | è»Ÿè†åŠ‘ | æ¿•ç–¹æ¨£çš®è†šç‚ã€èŸ²å’¬å‚·ã€å°¿å¸ƒç–¹ã€çš®è†šæ”ç™¢åŠéæ•æ€§æˆ–ç™¼ç‚æ€§çš®è†šç–¾æ‚£ç­‰ |
| å…§è¡›è—¥è£½å­—ç¬¬000711è™Ÿ | æ™®åŠ›å¤šå¯§éŒ  | éŒ åŠ‘ | é¢¨æ¿•æ€§ç–¾æ‚£ã€æ”¯æ°£ç®¡æ°£å–˜ã€è…ç‚ç—‡å€™ç¾¤ã€éæ•æ€§çš®è†šç–¾æ‚£ |
| å…§è¡›è—¥è£½å­—ç¬¬004492è™Ÿ | â€œè¯ç³â€è¢ªé¢¨æ¿•é¾éŒ  | éŒ åŠ‘ | é¢¨æ¿•æ€§é—œç¯€ç‚ã€çš®è†šç‚ã€æ”¯æ°£ç®¡ç‚ã€æ°£å–˜ã€éæ•æ€§ç–¾æ‚£ |

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼šPrednisolone èˆ‡å¤šç¨®è—¥ç‰©æœ‰ä¸­ç­‰ç¨‹åº¦çš„äº¤äº’ä½œç”¨ï¼Œä¾‹å¦‚ Zidovudineã€Abametapir (topical)ã€Isotretinoin ç­‰ã€‚
- **ä¸»è¦äº¤äº’ä½œç”¨**ï¼šèˆ‡ Adalimumab æœ‰é‡å¤§äº¤äº’ä½œç”¨ã€‚

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**ç”˜è‰** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”˜è‰å»¶é•·çš®è³ªé¡å›ºé†‡ä½œç”¨ï¼Œå¢åŠ å‰¯ä½œç”¨é¢¨éšª
- å»ºè­°ï¼šé¿å…é«˜åŠ‘é‡ç”˜è‰


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Latent Tuberculosis** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**Fibrosis** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**Psychotic Disorders** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**ç³–å°¿ç—…** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šé«˜è¡€ç³–ã€‚

**Water-Electrolyte Imbalance** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šç™²ç™‡ç™¼ä½œã€‚

**Water-Electrolyte Imbalance** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šCorticosteroids may cause hypernatremia, hypokalemia, fluid retention, and elevation in blood pressure...

**Peptic Ulcer Perforation** ğŸŸ¡ Moderate
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå‡ºè¡€ã€æ„ŸæŸ“ã€‚

**Cushing Syndrome** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šCorticosteroids mimic the effects of endogenous cortisol and aldosterone...

**Hyperlipidemias** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**ç”²ç‹€è…ºæ©Ÿèƒ½ä½ä¸‹** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**Myocardial Infarction** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**é‡ç—‡è‚Œç„¡åŠ›** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Muscular Diseases** ğŸŸ¡ Moderate
- å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Keratitis, Herpetic** ğŸŸ¡ Moderate
- ä¸å»ºè­°ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**Toxic Optic Neuropathy** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šProlonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma...

**éª¨è³ªç–é¬†ç—‡** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šCorticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss durin...

**æ¶ˆåŒ–æ€§æ½°ç˜** ğŸŸ¡ Moderate
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå‡ºè¡€ã€‚

**Scleroderma, Localized** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šIn patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in reni...

**Strongyloidiasis** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**Thromboembolism** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šè¡€æ “ã€‚

**Infections** ğŸŸ¢ Minor
- ä¸æ‡‰ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚å¯èƒ½å±åŠç”Ÿå‘½ã€‚

**Premature Birth** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šå…’ç«¥ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Prednisolone åœ¨æ–‘ç¦¿çš„æ²»ç™‚ä¸­å·²æœ‰å¤šå€‹è‡¨åºŠè©¦é©—å’Œæ–‡ç»æ”¯æŒï¼Œé¡¯ç¤ºå…¶å¯èƒ½çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é€²ä¸€æ­¥çš„æ©Ÿè½‰ç ”ç©¶ä»¥ç¢ºèªå…¶åœ¨æ–‘ç¦¿ä¸­çš„ä½œç”¨æ©Ÿåˆ¶
- ç‰¹å®šæ—ç¾¤çš„å®‰å…¨æ€§ç›£æ¸¬è¨ˆç•«

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Human Immunoglobulin G]({{ "/drugs/human_immunoglobulin_g/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Durvalumab]({{ "/drugs/durvalumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Lornoxicam]({{ "/drugs/lornoxicam/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Dupilumab]({{ "/drugs/dupilumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Interferon Beta-1B]({{ "/drugs/interferon_beta-1b/" | relative_url }}) - è­‰æ“šç­‰ç´š L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Prednisoloneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/prednisolone/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_prednisolone,
  title = {Prednisoloneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/prednisolone/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
